114 related articles for article (PubMed ID: 28816016)
1. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer.
Kandil S; Prencipe F; Jones S; Hiscox S; Westwell AD
Chem Biol Drug Des; 2018 Jan; 91(1):314-321. PubMed ID: 28816016
[TBL] [Abstract][Full Text] [Related]
2. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer.
Kandil SB; Jones SR; Smith S; Hiscox SE; Westwell AD
Molecules; 2020 Jul; 25(15):. PubMed ID: 32751931
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
[TBL] [Abstract][Full Text] [Related]
4. SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.
Burgess JT; Bolderson E; Saunus JM; Zhang SD; Reid LE; McNicol AM; Lakhani SR; Cuff K; Richard K; Richard DJ; O'Byrne KJ
Oncotarget; 2016 Nov; 7(45):72807-72818. PubMed ID: 27637080
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel chloropyramine-cinnamic acid hybrids as potential FAK inhibitors for intervention of metastatic triple-negative breast cancer.
Yang F; Xu K; Zhang S; Zhang J; Qiu Y; Luo J; Tan G; Zou Z; Wang W; Kang F
Bioorg Med Chem; 2022 Jul; 66():116809. PubMed ID: 35569251
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG
Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592
[TBL] [Abstract][Full Text] [Related]
7. Small molecule chloropyramine hydrochloride (C4) targets the binding site of focal adhesion kinase and vascular endothelial growth factor receptor 3 and suppresses breast cancer growth in vivo.
Kurenova EV; Hunt DL; He D; Magis AT; Ostrov DA; Cance WG
J Med Chem; 2009 Aug; 52(15):4716-24. PubMed ID: 19610651
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of FAK and VEGFR-3 binding decreases tumorigenicity in neuroblastoma.
Stewart JE; Ma X; Megison M; Nabers H; Cance WG; Kurenova EV; Beierle EA
Mol Carcinog; 2015 Jan; 54(1):9-23. PubMed ID: 23868727
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
[TBL] [Abstract][Full Text] [Related]
10. Marine natural products-inspired phenylmethylene hydantoins with potent in vitro and in vivo antitumor activities via suppression of Brk and FAK signaling.
Sallam AA; Mohyeldin MM; Foudah AI; Akl MR; Nazzal S; Meyer SA; Liu YY; El Sayed KA
Org Biomol Chem; 2014 Jul; 12(28):5295-303. PubMed ID: 24927150
[TBL] [Abstract][Full Text] [Related]
11. Antiproliferative and antimetastatic properties of 3-benzyloxy-16-hydroxymethylene-estradiol analogs against breast cancer cell lines.
Sinka I; Kiss A; Mernyák E; Wölfling J; Schneider G; Ocsovszki I; Kuo CY; Wang HC; Zupkó I
Eur J Pharm Sci; 2018 Oct; 123():362-370. PubMed ID: 30010030
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological, Mechanistic, and Pharmacokinetic Assessment of Novel Melatonin-Tamoxifen Drug Conjugates as Breast Cancer Drugs.
Hasan M; Marzouk MA; Adhikari S; Wright TD; Miller BP; Matossian MD; Elliott S; Wright M; Alzoubi M; Collins-Burow BM; Burow ME; Holzgrabe U; Zlotos DP; Stratford RE; Witt-Enderby PA
Mol Pharmacol; 2019 Aug; 96(2):272-296. PubMed ID: 31221824
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA
Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490
[TBL] [Abstract][Full Text] [Related]
14. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation, and molecular docking studies of 1,3,4-thiadiazol-2-amide derivatives as novel anticancer agents.
Yang XH; Xiang L; Li X; Zhao TT; Zhang H; Zhou WP; Wang XM; Gong HB; Zhu HL
Bioorg Med Chem; 2012 May; 20(9):2789-95. PubMed ID: 22503364
[TBL] [Abstract][Full Text] [Related]
16. A FAK scaffold inhibitor disrupts FAK and VEGFR-3 signaling and blocks melanoma growth by targeting both tumor and endothelial cells.
Kurenova E; Ucar D; Liao J; Yemma M; Gogate P; Bshara W; Sunar U; Seshadri M; Hochwald SN; Cance WG
Cell Cycle; 2014; 13(16):2542-53. PubMed ID: 25486195
[TBL] [Abstract][Full Text] [Related]
17. Phosphamide-containing diphenylpyrimidine analogues (PA-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with enhanced activity against pancreatic cancer cell lines.
Liu H; Wu B; Ge Y; Huang J; Song S; Wang C; Yao J; Liu K; Li Y; Li Y; Ma X
Bioorg Med Chem; 2017 Dec; 25(24):6313-6321. PubMed ID: 29102081
[TBL] [Abstract][Full Text] [Related]
18. The FAK scaffold inhibitor C4 disrupts FAK-VEGFR-3 signaling and inhibits pancreatic cancer growth.
Kurenova E; Liao J; He DH; Hunt D; Yemma M; Bshara W; Seshadri M; Cance WG
Oncotarget; 2013 Oct; 4(10):1632-46. PubMed ID: 24142503
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and molecular docking of novel 2-arylbenzothiazole multiangiokinase inhibitors targeting breast cancer.
Abdel-Mohsen HT; Abd El-Meguid EA; El Kerdawy AM; Mahmoud AEE; Ali MM
Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900340. PubMed ID: 32045054
[TBL] [Abstract][Full Text] [Related]
20. Cucurbitacin B suppresses metastasis mediated by reactive oxygen species (ROS) via focal adhesion kinase (FAK) in breast cancer MDA-MB-231 cells.
Luo WW; Zhao WW; Lu JJ; Wang YT; Chen XP
Chin J Nat Med; 2018 Jan; 16(1):10-19. PubMed ID: 29425586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
